Irma Egoavil – Country Manager, Celgene Mexico
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Celgene is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, and ISTODAX. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Contact details
Celgene México
Juan Salvador Agraz 65, Piso 17,
Colonia Lomas de Santa Fe.
C.P. 05300. México, D.F.
MEXICO
Tel: +52 (55) 41236700
Website: www.celgene.com
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Thanks to the recognition COFEPRIS received from the Pan-American Health Organization as national regulatory authority of regional reference, Mexican manufacturers are increasingly eyeing foreign markets to grow. The general manager…
Healthcare is one of the next items on President Peña Nieto’s busy agenda. The objective: moving Mexico towards universal healthcare coverage. The initiative was started at the beginning of 2000…
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Dr. José Angel Cordova Villalobos shares his experience as former Minister of Health and illustrates how the unification of today’s fragmented healthcare system is the only way to provide effective…
The opening of the Mexican Social Security Institute (IMSS) to clinical research is a unique opportunity for Mexico to step up on the international scenario for clinical trials. The CEO of…
Store brands are Perrigo’s core business. The vice president and managing director of the Mexican and Latin American affiliate discusses the company’s pioneer and early vision to bet on generics…
The executive director of the university spin-off UDIMEB explains the major achievements of the institution, her plans to convert it into a strategic partner to the pharmaceutical and biotechnology industry to…
The partner and leader of the healthcare practice for Mexico and Hispanic America shares his vision about how Mexico’s healthcare sector is converging to look at innovative ways to understand…
Healthcare should not be seen as an expenditure, but rather as an investment. Mexico’s former minister of health and current dean at the Harvard T.H. Chan School of Public Health…
Mr Carlos Jimenez of B. Braun Aesculap sat down with us and shared his personal beliefs on Mexico’s market potential for medical equipment, how the country can create more momentum…
Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for…
Clinical research and access are the name of the game. The Executive Director of the association bringing together the most important research-based pharmaceutical companies discusses how the association has stepped…
See our Cookie Privacy Policy Here